CytoDyn (CYDY) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on developing leronlimab, a monoclonal antibody targeting CCR5, for solid-tumor oncology and other indications.

• Current strategy includes advancing a Phase 2 trial in relapsed/refractory microsatellite stable colorectal cancer, exploring additional solid-tumor indications, and developing a long-acting version of leronlimab.

• Pursues non-dilutive financing such as licensing and strategic partnerships alongside traditional fundraising.

Financial performance and metrics

• As of February 28, 2026, cash and cash equivalents totaled $15.7 million, with short-term liabilities of $50.4 million.

• Nine months ended February 28, 2026: net loss of $32.8 million; prior year period showed net income of $9.7 million due to a one-time legal settlement.

• Fiscal year ended May 31, 2025: net income of $3.7 million, primarily from a $25 million legal settlement; otherwise, history of significant operating losses.

• Accumulated deficit of $920.6 million as of February 28, 2026.

• Auditors issued a going concern opinion due to recurring losses and working capital deficiency.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; company may receive up to $23.9 million if all warrants are exercised for cash.

• Any proceeds from warrant exercises will be used for working capital and general corporate purposes.